GlassScriptPhysician profile
Heather D Mata
NPI 1932772399
$862.25
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $287 · 2024: $289 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.26 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $177.73 | 2024-2025 | Veozah |
| Abbvie INC. | $109.15 | 2023-2025 | |
| Novo Nordisk INC | $101.43 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $87.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ascendis Pharma Endocrinology INC | $64.54 | 2025 | Yorvipath |
| Myriad Women'S Health, INC. | $62.00 | 2023 | Myrisk |
| Tempus Ai, INC | $45.72 | 2024 | |
| Coopersurgical, INC. | $40.57 | 2023 | Paragard T 380a |
| Axsome Therapeutics, INC. | $38.78 | 2023-2025 | Auvelity |
| Pfizer INC. | $34.62 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $33.15 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $27.26 | 2025 | Trintellix |
| Inspire Medical Systems, INC. | $22.44 | 2025 | Inspire |
| Lilly USA, LLC | $17.05 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.